Avectas is a cell engineering business, enabling the manufacture of cell therapies. Avectas’ technology, SOLUPORE®, delivers advanced molecules such as DNA, mRNA, proteins and gene editing tools to a range of primary cell types including T cells and NK cells for immuno-oncology and gene editing applications. We seek cell therapeutic developers to partner in the development of next-generation cell therapies using our SOLUPORE® non-viral delivery platform. The SOLUPORE® technology is versatile and enables delivery of nucleic acids such as mRNA, DNA and proteins, including gene-editing tools such as CRISPR. The SOLUPORE® cell engineering platform achieves excellent engineering efficiencies in a variety of cell types including primary T cells and NK cells for immuno-oncology and gene editing applications.